Fig 1: miR-218 regulates the proliferation and migration of ccRCC by targeting CIP2A. (A) Alteration of the CIP2A protein expression levels in Caki-1 and 786-O cell lines transfected with si-CIP2A or NC siRNA. ***P<0.001 vs. NC siRNA. (B) Cell proliferation and (C) cell migration in Caki-1 and 786-O cell lines transfected with miR-218 inhibitor, si-CIP2A or NC siRNA. **P<0.01 and ***P<0.001. Data are presented as the mean ± standard deviation. miR-218, microRNA-218; NC miRNA, negative control microRNA; ccRCC, clear cell renal cell carcinoma; CIP2A, cancerous inhibitor of protein phosphatase 2A; OD, optical density; si, small interfering.
Fig 2: miR-218 inhibits CIP2A expression by specifically targeting its 3'-UTR. (A) Sequence alignment of the CIP2A WT and CIP2A MUT potential miR-218 targeting sites. (B) Luciferase reporter assay demonstrated decreased reporter activity following transfection with the CIP2A WT in Caki-1 and 786-O cell lines overexpressing miR-218. (C) Inverse correlation between miR-218 expression level and CIP2A expression level in ccRCC tissues. (D) Alteration of the CIP2A protein expression levels in Caki-1 and 786-O cell lines transfected with miR-218 mimic or NC miRNA. Data are presented as the mean ± standard deviation. ***P<0.001 vs. NC miRNA. miR-218, microRNA-218; ccRCC, clear cell renal cell carcinoma; UTR, untranslated region; WT, wild-type; MUT, mutant; CIP2A, cancerous inhibitor of protein phosphatase 2A; NC miRNA, negative control microRNA.
Supplier Page from Abcam for Anti-CIP2A antibody [2A1-9A4]